México Mercado de Pruebas Genéticas Tamaño, Participación, Tendencias y Pronóstico por Tipo, Tecnología, Aplicación y Región, 2026-2034

Overview of the Genetic Testing Market in Mexico:

The genetic testing market in Mexico reached USD 321.0 million in 2025. Looking ahead, IMARC Group expects the market to reach USD 712.5 million by 2034 , exhibiting a compound annual growth rate (CAGR) of 8.98% during 2026–2034 . The market is growing due to increasing demand for personalized medicine, greater awareness of preventive healthcare, and increased accessibility to direct-to-consumer (DTC) testing. Advances in prenatal and newborn screening, along with private sector investments and government health initiatives, are further driving its adoption. However, affordability and regulatory clarity remain key challenges for greater market penetration.

Trends in the genetic testing market in Mexico:

Growth of oncological genetic testing for precision cancer treatment

Cancer genetic testing is gaining traction in Mexico as healthcare providers increasingly adopt precision medicine approaches to cancer treatment. Tests such as next-generation sequencing (NGS) and liquid biopsies are being used to identify genetic mutations and biomarkers, enabling targeted therapies and improved patient outcomes. The rising incidence of cancer, coupled with increasing awareness of genetic predisposition to malignant tumors, is fueling the growth of the genetic testing market in Mexico. Cancer is the fourth leading cause of death in Mexico, with approximately 46,200 premature deaths annually, and per capita healthcare spending on cancer is projected to increase by 106% by 2050. Improved detection and treatment methods could prevent 50% of these premature deaths, create 13,000 full-time jobs, and increase life expectancy by an average of five months. These results would make a significant difference if implemented effectively. Furthermore, HPV vaccination can also prevent 84% of cervical cancer deaths, resulting in annual savings of MXN 1.323 billion (approximately USD 73 million) in healthcare costs. Private hospitals and diagnostic chains are partnering with global biotechnology companies to offer advanced genomic profiling services. However, high costs and limited insurance coverage restrict access for many patients. Government efforts to expand cancer screening programs and partnerships with research institutions are expected to improve adoption. As the technology becomes more affordable and awareness increases, genetic cancer testing will play a critical role in the fight against cancer, creating a positive outlook for the genetic testing market in Mexico.

Expansion of prenatal and neonatal genetic testing in Mexico

Otra tendencia clave del mercado es la creciente adopción del cribado genético prenatal y neonatal. Con la creciente concienciación sobre los trastornos genéticos y los avances en las pruebas prenatales no invasivas (NIPT), cada vez más futuros padres optan por el cribado precoz para detectar enfermedades como el síndrome de Down y la fibrosis quística. Un estudio de 182 pacientes mexicano-mestizos con síndrome de Lynch reveló que el 67,5% presentaba mutaciones en MLH1, y la variante MLH1 c.676C>T se halló en el 17,5% de los probandos. Aunque los resultados de las pruebas familiares se comunicaron a todo el mundo, sólo el 28,2% de los 451 familiares en situación de riesgo se sometieron a pruebas en cascada, lo que indica la necesidad de mejorar la comunicación y el acceso dentro del programa de cribado del cáncer hereditario en México. Las iniciativas gubernamentales y los proveedores sanitarios privados están promoviendo estas pruebas para reducir la mortalidad infantil y mejorar la atención neonatal. Además, el aumento de la edad materna y de la renta disponible contribuyen al crecimiento del mercado. Los laboratorios y hospitales privados se están asociando con empresas internacionales de pruebas genéticas para ofrecer soluciones de diagnóstico avanzadas. Por otra parte, la mejora de las infraestructuras sanitarias, las pruebas genéticas prenatales y neonatales y la mejora de los resultados sanitarios también están ampliando la cuota de mercado de las pruebas genéticas en México.

Segmentación del mercado de pruebas genéticas en México:

El Grupo IMARC ofrece un análisis de las tendencias clave en cada segmento del mercado, junto con previsiones a escala nacional y regional para 2026-2034. Nuestro informe ha categorizado el mercado en función del tipo, la tecnología y la aplicación.

Tipo Insights:

• Pruebas predictivas y presintomáticas
• Pruebas de portadores
• Pruebas prenatales y neonatales
• Pruebas diagnósticas
• Pruebas farmacogenómicas
• Otros

El informe ofrece un desglose y un análisis detallados del mercado en función del tipo. Esto incluye pruebas predictivas y presintomáticas, pruebas de portadores, pruebas prenatales y neonatales, pruebas diagnósticas, pruebas farmacogenómicas y otras.

Perspectivas tecnológicas:

• Pruebas citogenéticas y análisis cromosómico
• Pruebas bioquímicas
• Pruebas moleculares
  • Secuenciación del ADN
  • Otros

El informe también ofrece un desglose y un análisis detallados del mercado en función de la tecnología. Esto incluye pruebas citogenéticas y análisis cromosómicos, pruebas bioquímicas y pruebas moleculares (secuenciación del ADN y otras).

Perspectivas de aplicación:

• Diagnóstico del cáncer
• Diagnóstico de enfermedades genéticas
• Diagnóstico de enfermedades cardiovasculares
• Otros

El informe ofrece un desglose y un análisis detallados del mercado en función de la aplicación. Esto incluye el diagnóstico del cáncer, el diagnóstico de enfermedades genéticas, el diagnóstico de enfermedades cardiovasculares y otros.

Perspectivas regionales:

• Norte de México
• Central Mexico
• Southern Mexico
• Others

The report also provided a comprehensive analysis of key regional markets, including northern Mexico, central Mexico, southern Mexico, and others.

Competitive landscape:

The market research report also provides a comprehensive analysis of the competitive landscape. This includes competitive analysis such as market structure, key player positioning, leading winning strategies, a competitive dashboard, and a company assessment quadrant. Detailed profiles of the top companies are also provided.

Coverage of the report on the genetic testing market in Mexico:

Key questions answered in this report:

• How has the genetic testing market in Mexico performed so far, and how will it perform in the coming years?
• What is the distribution of the genetic testing market in Mexico by type?
• What is the breakdown of the Mexican genetic testing market based on technology?
• What is the breakdown of the genetic testing market in Mexico based on application?
• How is the genetic testing market distributed in Mexico by region?
• What are the different stages of the value chain in the genetic testing market in Mexico?
• What are the main driving factors and challenges of the genetic testing market in Mexico?
• What is the structure of the genetic testing market in Mexico and who are its main players?
• What is the level of competition in the genetic testing market in Mexico?

Main benefits for stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and market dynamics for genetic testing in Mexico from 2020 to 2034.
• The research report provides the latest information on market drivers, challenges, and opportunities in the Mexican genetic testing market.
• Porter's Five Forces analysis helps stakeholders assess the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition in the genetic testing sector in Mexico and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of the major market players.